Promimic AB (publ) (PRO.ST)
SEK 25.8
(-1.15%)
SEK 25.8
(-1.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.11 Million SEK | 43.95% |
| 2022 | -16.37 Million SEK | -4.87% |
| 2021 | -15.61 Million SEK | -9.92% |
| 2020 | -14.2 Million SEK | -27.55% |
| 2019 | -11.13 Million SEK | 26.94% |
| 2018 | -15.24 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.76 Million SEK | 5.31% |
| 2024 Q2 | -2.2 Million SEK | 41.34% |
| 2023 Q1 | -3.5 Million SEK | 7.88% |
| 2023 FY | -9.17 Million SEK | 43.95% |
| 2023 Q4 | -3.97 Million SEK | -319.75% |
| 2023 Q2 | -1.42 Million SEK | 59.5% |
| 2023 Q3 | -947 Thousand SEK | 33.31% |
| 2022 Q4 | -3.8 Million SEK | -39.36% |
| 2022 Q3 | -2.73 Million SEK | 41.84% |
| 2022 Q2 | -4.69 Million SEK | 12.4% |
| 2022 Q1 | -5.36 Million SEK | -22.82% |
| 2022 FY | -16.37 Million SEK | -4.87% |
| 2021 Q1 | -3.63 Million SEK | 0.0% |
| 2021 FY | -15.61 Million SEK | -9.92% |
| 2021 Q2 | -4.51 Million SEK | -24.2% |
| 2021 Q4 | -4.36 Million SEK | -35.22% |
| 2021 Q3 | -3.22 Million SEK | 28.52% |
| 2020 FY | -14.2 Million SEK | -27.55% |
| 2019 FY | -11.13 Million SEK | 26.94% |
| 2018 FY | -15.24 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 88.243% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 103.033% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 103.033% |
| Arcoma AB | 4.66 Million SEK | 295.665% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 93.089% |
| BICO Group AB (publ) | -618.3 Million SEK | 98.525% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 123.219% |
| CellaVision AB (publ) | 167.05 Million SEK | 105.458% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 86.171% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 69.166% |
| C-Rad AB (publ) | 44.24 Million SEK | 120.608% |
| Duearity AB (publ) | -25.76 Million SEK | 64.608% |
| Dignitana AB (publ) | -15.02 Million SEK | 39.319% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 90.382% |
| Getinge AB (publ) | 3.81 Billion SEK | 100.239% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 86.679% |
| Iconovo AB (publ) | -45.77 Million SEK | 80.082% |
| Integrum AB (publ) | 6.51 Million SEK | 240.011% |
| Luxbright AB (publ) | -25.8 Million SEK | 64.665% |
| Mentice AB (publ) | -679 Thousand SEK | -1242.857% |
| OssDsign AB (publ) | -91.95 Million SEK | 90.084% |
| Paxman AB (publ) | 12.61 Million SEK | 172.256% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 94.595% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 83.096% |
| ScandiDos AB (publ) | -13.48 Million SEK | 32.374% |
| Sectra AB (publ) | 518.49 Million SEK | 101.759% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 86.089% |
| Senzime AB (publ) | -133.74 Million SEK | 93.183% |
| SpectraCure AB (publ) | -21.35 Million SEK | 57.295% |
| Stille AB | 44.95 Million SEK | 120.284% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 99.746% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 123.679% |